Literature DB >> 35125728

Adenoviral Subacute Focal Meningoencephalitis Complicating Polatuzumab, Bendamustine and Rituximab Chemo-Immunotherapy for Aggressive B-Cell Lymphoma.

Gurvin Chander1, Emmanouil Nikolousis1, Husam Osman2, Ellen Shirley1, Bhuvan Kishore1, Richard Lovell1, Jayna Mistry1, Shankara Paneesha1, Alexandros Kanellopoulos3,4.   

Abstract

Entities:  

Year:  2021        PMID： 35125728      PMCID： PMC8804018          DOI： 10.1007/s12288-021-01456-3

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.900


× No keyword cloud information.
  3 in total

1.  Human adenovirus meningoencephalitis: a 3-years' overview.

Authors:  Luine Rosele Vidal; Sérgio Monteiro de Almeida; Bárbara Maria Cavalli; Tatiana Gutierrez Dieckmann; Sonia Mara Raboni; Gabriel L O Salvador; Luciane Aparecida Pereira; Indianara Rotta; Meri Bordignon Nogueira
Journal:  J Neurovirol       Date:  2019-05-17       Impact factor: 2.643

2.  Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis.

Authors:  Nicolás Martínez-Calle; Sarah Hartley; Matthew Ahearne; Benjamin Kasenda; Amy Beech; Helen Knight; Constantine Balotis; Ben Kennedy; Simon Wagner; Martin J S Dyer; Dean Smith; Andrew K McMillan; Fiona Miall; Mark Bishton; Christopher P Fox
Journal:  Br J Haematol       Date:  2018-12-13       Impact factor: 6.998

3.  Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Authors:  Laurie H Sehn; Alex F Herrera; Christopher R Flowers; Manali K Kamdar; Andrew McMillan; Mark Hertzberg; Sarit Assouline; Tae Min Kim; Won Seog Kim; Muhit Ozcan; Jamie Hirata; Elicia Penuel; Joseph N Paulson; Ji Cheng; Grace Ku; Matthew J Matasar
Journal:  J Clin Oncol       Date:  2019-11-06       Impact factor: 44.544
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.